How much weight can you lose on Mounjaro?

The SURMOUNT-1 trial demonstrated average weight loss of 16% with 5mg, 19.5% with 10mg, and 22.5% with 15mg doses over 72 weeks. Individual results vary based on starting weight, lifestyle factors, and dose tolerance. Some participants achieved over 25% weight loss at the highest dose.

What's the difference between Mounjaro and Ozempic?

Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors, whilst Ozempic (semaglutide) only targets GLP-1 receptors. This dual mechanism typically produces greater weight loss with Mounjaro. Our semaglutide vs tirzepatide comparison provides detailed analysis of both treatments.

How much does Mounjaro cost privately in the UK?

Private Mounjaro prescriptions typically cost £200-300 monthly, depending on dose and provider. Higher doses cost more due to increased medication volume. Our cost calculator helps estimate total treatment expenses across different UK providers and dose levels.

What BMI do you need for Mounjaro?

For NHS prescribing, NICE criteria typically require BMI ≥35 with weight-related comorbidities or BMI ≥30 in specific circumstances such as recent type 2 diabetes diagnosis. Private providers may have different criteria, often accepting BMI ≥30 with appropriate medical justification.

Where do you inject Mounjaro?

Mounjaro can be injected subcutaneously in the abdomen (avoiding 5cm around the navel), upper arm, or thigh. Rotate injection sites weekly to prevent lipodystrophy. The KwikPen device makes self-injection straightforward, with most patients finding the abdomen most convenient and comfortable.

What are the common side effects of Mounjaro?

The most common side effects are gastrointestinal: nausea (up to 25%), diarrhoea (20%), decreased appetite (15%), and vomiting (8-12%). These typically occur during initial treatment or dose increases and often improve with continued use. Injection site reactions affect approximately 5-10% of users.

Can you drink alcohol while taking Mounjaro?

Moderate alcohol consumption is generally acceptable with Mounjaro, though alcohol may worsen gastrointestinal side effects like nausea and vomiting. Excessive alcohol increases hypoglycaemia risk, particularly in patients with diabetes. Consult your healthcare provider about alcohol consumption guidelines specific to your situation.

How long does it take for Mounjaro to work?

Appetite reduction typically begins within the first week of treatment. Weight loss becomes noticeable after 4-8 weeks, with maximum effects usually seen after 16-20 weeks at optimal dosing. The gradual dose escalation means full therapeutic effects develop over several months of treatment.

Is Mounjaro better than Wegovy for weight loss?

Clinical trials suggest Mounjaro produces greater weight loss than Wegovy due to its dual GIP/GLP-1 mechanism versus Wegovy's single GLP-1 action. SURMOUNT trials showed up to 22.5% weight loss with Mounjaro compared to 15% typically seen with Wegovy. Individual responses vary, and our Mounjaro vs Wegovy guide provides detailed comparison.

Do I need to refrigerate Mounjaro?

Yes, unused Mounjaro KwikPens must be stored in the refrigerator at 2-8°C. Once in use, pens can be stored at room temperature (below 30°C) for up to 21 days. Never freeze Mounjaro, and protect from direct sunlight. Our peptide storage guide covers proper handling procedures.

Can I stop taking Mounjaro suddenly?

While stopping Mounjaro abruptly isn't medically dangerous, weight regain typically occurs within months of discontinuation. The SURMOUNT-4 trial showed significant weight regain when treatment stopped. Discuss discontinuation plans with your healthcare provider to develop appropriate maintenance strategies and lifestyle modifications.

Fat Loss

Mounjaro

Also known as: Tirzepatide injection, Mounjaro KwikPen, Dual GIP/GLP-1 agonist, LY3298176

RouteSubcutaneous

UK StatusMounjaro received MHRA approval for type 2 diabetes treatment in 2022, followed by NICE recommendation (TA1026) for weight management in eligible adults in 2024. This dual approval pathway reflects the medication's proven efficacy in both metabolic conditions. NHS availability for weight management follows strict NICE criteria, typically requiring BMI ≥35 kg/m² with weight-related comorbidities or BMI ≥30 kg/m² in specific circumstances. Access varies significantly across Clinical Commissioning Groups, with some regions implementing Mounjaro through specialist weight management services whilst others maintain waiting lists due to budget constraints. Private prescription represents the most reliable access route, with numerous UK clinics and online services offering Mounjaro following appropriate medical assessment. Private costs typically range from £200-300 monthly, varying by dose and provider. The medication requires prescription-only medicine (POM) status, meaning pharmacy supply requires valid prescriptions from registered UK prescribers or recognised EU/international prescribers under specific circumstances. MHRA regulations ensure supply chain integrity through licensed wholesalers and pharmacies. Patients should verify provider credentials and avoid unlicensed sources, which may supply counterfeit or improperly stored products. The KwikPen delivery system requires refrigerated storage and proper disposal through healthcare waste systems.

Overview

What is Mounjaro?

Mounjaro is the brand name for tirzepatide, a revolutionary dual-action injection manufactured by Eli Lilly that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Unlike single-action treatments such as Ozempic or Wegovy, Mounjaro's dual mechanism of action has demonstrated superior weight loss results in clinical trials.

Approved by the MHRA for type 2 diabetes treatment and subsequently endorsed by NICE for weight management in 2024, Mounjaro represents the latest advancement in metabolic health treatment. The active ingredient tirzepatide works by mimicking two important incretin hormones simultaneously, resulting in enhanced glucose control and substantial weight reduction.

How Mounjaro Works: Dual Receptor Activation

Mounjaro's unique dual mechanism sets it apart from semaglutide-based treatments. By activating both GIP and GLP-1 receptors, it creates a more comprehensive metabolic response:

GLP-1 receptor activation slows gastric emptying, reduces appetite, and enhances insulin secretion
GIP receptor activation provides additional glucose-dependent insulin release and may influence fat metabolism
Combined effect produces greater weight loss and improved glycaemic control compared to single-receptor agonists

This dual approach explains why Mounjaro typically produces more significant weight loss than Wegovy in head-to-head comparisons, as detailed in our Mounjaro vs Wegovy analysis.

Mounjaro Dosage Schedule

Mounjaro follows a structured six-dose titration protocol designed to minimise side effects whilst maximising efficacy:

Week 1-4: 2.5mg weekly (starting dose) Week 5-8: 5mg weekly Week 9-12: 7.5mg weekly Week 13-16: 10mg weekly Week 17-20: 12.5mg weekly Week 21+: 15mg weekly (maximum maintenance dose)

Patients typically remain at each dose level for four weeks, though healthcare providers may adjust timing based on individual tolerance and response. The gradual increase helps reduce gastrointestinal side effects commonly experienced with GLP-1 receptor agonists.

Clinical Trial Results: SURMOUNT Studies

The SURMOUNT clinical trial programme has demonstrated Mounjaro's exceptional efficacy across multiple populations. SURMOUNT-1, involving 2,539 adults with obesity or overweight conditions, showed remarkable weight loss results at 72 weeks:

2.5mg dose: 16% average weight loss
5mg dose: 19.5% average weight loss
15mg dose: 22.5% average weight loss

SURMOUNT-2 specifically studied people with type 2 diabetes, demonstrating 15.7% weight loss with the 15mg dose whilst improving glycaemic control. These results significantly exceed those seen with single-receptor agonists in comparable trials.

Injection Sites and Administration

Mounjaro is administered via subcutaneous injection using the KwikPen device. Recommended injection sites include:

Abdomen: Most common site, avoid 5cm around navel
Upper arm: Outer area with adequate subcutaneous tissue
Thigh: Front or outer areas

Rotating injection sites weekly helps prevent lipodystrophy and maintains consistent absorption. Our peptide storage guide provides detailed information on proper handling and storage requirements.

NHS Availability and NICE Criteria

Following NICE approval (TA1026) in 2024, Mounjaro is available through specialist NHS weight management services for eligible patients. NICE criteria typically include:

BMI ≥35 kg/m² with at least one weight-related comorbidity
BMI ≥30 kg/m² in specific circumstances (such as recent type 2 diabetes diagnosis)
Previous unsuccessful weight management attempts
Commitment to lifestyle modification programmes

NHS availability varies by region, with some areas experiencing longer waiting times due to high demand. Private prescription remains the fastest route to access, though costs are typically higher than Wegovy. Our cost calculator helps estimate treatment expenses across different providers.

Side Effects and Tolerability

Mounjaro's side effect profile is similar to other GLP-1 receptor agonists, though the dual mechanism may influence frequency and severity. The gradual dose escalation protocol helps minimise gastrointestinal effects, which remain the most common adverse reactions.

Comparing Mounjaro to Other Treatments

When evaluating Mounjaro against alternatives, the dual receptor mechanism consistently demonstrates superior weight loss outcomes. Our comprehensive comparison tool allows direct evaluation against Wegovy, Ozempic, and other metabolic treatments, helping patients and healthcare providers make informed decisions based on individual circumstances and treatment goals.

Mechanism of Action

Tirzepatide, the active ingredient in Mounjaro, functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual mechanism represents a significant advancement over single-receptor agonists like semaglutide.

The GLP-1 receptor activation component works by binding to GLP-1 receptors primarily located in pancreatic beta cells, the gastrointestinal tract, and hypothalamus. This binding triggers several physiological responses: enhanced glucose-dependent insulin secretion, suppression of inappropriate glucagon release from pancreatic alpha cells, delayed gastric emptying, and reduced food intake through central appetite regulation.

Simultaneously, tirzepatide activates GIP receptors, which are found in pancreatic beta and alpha cells, adipose tissue, and bone. GIP receptor activation provides additional glucose-dependent insulin release and may influence lipid metabolism and bone formation. The GIP pathway appears particularly important for postprandial (after-meal) glucose control and may contribute to the superior weight loss seen with dual agonists.

The glucose-dependent nature of both mechanisms means insulin secretion only occurs when blood glucose levels are elevated, significantly reducing hypoglycaemia risk compared to traditional diabetes medications. The combined receptor activation creates synergistic effects on metabolism, resulting in greater weight loss and improved glycaemic control than either pathway alone could achieve.

Discover More

Find Your Best Match

Not sure which peptide is right for you?

Browse our goal-based guides to find the best peptide for muscle growth, fat loss, recovery, and more.

Compare by goal →

Frequently Asked Questions

Common questions about Mounjaro

Yes, Mounjaro is available on the NHS following NICE approval in 2024 for weight management. Eligibility requires BMI ≥35 with weight-related conditions or BMI ≥30 in specific circumstances. Access varies by region, with some areas having waiting lists due to high demand and budget constraints.